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CD-1 mice were exposed to baseline gasoline vapor condensate (BGVC) alone or to vapors of gasoline
blended with methyl tertiary butyl ether (G/MTBE). Inhalation exposures were 6 h/d on GD 5–17 at levels
of 0, 2000, 10,000, and 20,000 mg/m3. Dams were evaluated for evidence of maternal toxicity, and fetuses
were weighed, sexed, and evaluated for external, visceral, and skeletal anomalies. Exposure to 20,000mg/m3
of BGVC produced slight reductions in maternal body weight/gain and decreased fetal body weight. G/MTBE
exposure did not produce statistically signiﬁcant maternal or developmental effects; however, two
uncommon ventral wall closure defects occurred: gastroschisis (1 fetus at 10,000 mg/m3) and ectopia
cordis (1 fetus at 2000 mg/m3; 2 fetuses/1 litter at 10,000 mg/m3). A second study (G/MTBE-2) evaluated
similar exposure levels on GD 5–16 and an additional group exposed to 30,000 mg/m3 from GD 5–10.
An increased incidence of cleft palate was observed at 30,000 mg/m3 G/MTBE. No ectopia cordis
occurred in the replicate study, but a single observation of gastroschisis was observed at 30,000mg/m3.
The no observed adverse effect levels for maternal/developmental toxicity in the BGVC study were
10,000/2000 mg/m3, 20,000/20,000 for the G/MTBE study, and 10,000/20,000 for the G/MTBE-2 study.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The 1990 amendments to the Clean Air Act (CAA) mandated the
use of oxygenates in motor gasoline. In 1994, the U.S. Environmen-
tal Protection Agency (EPA) issued a ﬁnal rule under the Act which
added new health effects information and testing requirements to
the Agency’s existing registration requirements. As described inmore detail in a companion paper (Henley et al., 2014), require-
ments include inhalation exposures to evaporative emissions of
the gasoline or gasoline blended with the additive in question.
The health endpoints include assessments for standard subchronic
toxicity, neurotoxicity, genotoxicity, immunotoxicity, develop-
mental and reproductive toxicity, and chronic toxicity/carcinoge-
nicity. The results of chronic toxicity testing of gasoline and
gasoline combined with MTBE have already been reported
(Benson et al., 2011) and reported elsewhere in this issue are the
ﬁndings for subchronic toxicity testing (Clark et al., 2014), geno-
toxicity (Schreiner et al., 2014), neurotoxicity (O’Callaghan et al.,
2014) and immunotoxicity (White et al., 2014). This paper
describes the results of developmental toxicity testing in mice
which have been submitted to EPA. Other papers in this issue
report on the results of developmental and reproductive toxicity
testing in rats (Roberts et al., 2014; Gray et al., 2014).
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Two studies to meet the CAA requirements were conducted at
ExxonMobil Biomedical Sciences, Inc. (EMBSI) Laboratory Opera-
tions, Mammalian Toxicology Laboratory, 1545 Route 22 East,
P.O. Box 971, Annandale, New Jersey 08801. The test materials
were a baseline gasoline vapor condensate (BGVC) and a vapor
condensate of gasoline mixed with methyl-t-butyl ether (G/MTBE).
Due to an unusual ﬁnding in the G/MTBE study, a repeat of the
G/MTBE study was conducted at Huntingdon Life Sciences (HLS),
Princeton Research Center, 100 Mettlers Road, East Millstone, NJ.
The postmortem maternal and fetal evaluations and analyses were
conducted by staff of RTI International (RTI), POB 12194, 3040
Cornwallis Road, Research Triangle Park, NC, 27709, at the HLS
testing facility. All of the laboratories are accredited by the Associ-
ation for Assessment and Accreditation of Laboratory Animal Care
(AAALAC International).2.1. CAA Studies
2.1.1. Test material preparation and characterization
Test articles included two different vapor condensates: one pre-
pared from an EPA-described ‘‘baseline gasoline’’ (BGVC) (US EPA,
1994), and the other from BGVC blended with methyl-t-butyl ether
(G/MTBE) prepared and supplied in 100 gal gas cylinders by Chev-
ron Research and Technology Center (Richmond, CA). The method-
ology for preparation and analytical characterization of the
samples is described in a companion paper (Henley, et al., 2014).
The test substances, as received, were considered the ‘‘pure’’ sub-
stance for the purpose of dosing.2.1.2. Animal selection and care
The test animals were Caesarean-originated Virus Antibody
Free (VAF) Crl:CD-1 (ICR) BR outbred albino mice supplied by
Charles River Laboratories, Inc.(Portage, MI). Sexually mature
males were used for mating purposes only. Females were 12–
13 weeks of age and weighed 26–35 g at the start of mating.
Certiﬁed Rodent Diet, No. 5002; (Meal) (PMI Nutrition Interna-
tional, St. Louis, Missouri) was available ad libitum. Analysis of
each feed lot used during this study was performed by the manu-
facturer. Water was available without restriction via an automated
watering system. There were no known contaminants in the feed
or water to interfere with test results of these studies. Animals
were without food and water while in the exposure chambers.2.1.3. Housing and environmental conditions
Animals were housed individually in suspended stainless steel
wire mesh cages. A twelve hour light/dark cycle was controlled
by an automatic timer. Temperature and relative humidity were
maintained within the speciﬁed range (64–72 degrees F, and 30–
70%, respectively).2.1.4. Experimental design
The experimental design is shown in Table 1. Untreated animals
were mated (1 nulliparous female; 1 male) until sufﬁcient plug
positive presumed-pregnant females were identiﬁed by the pres-
ence of a copulatory plug in the vagina. Plug-positive female mice
were distributed by body weight into four different exposure
groups (25/group) on gestational day (GD) 0. Presumed pregnant
females were exposed to 0 mg/m3 (air control), 2000 mg/m3,
10,000 mg/m3 and 20,000 mg/m3, 6 h/day from GD 5 through GD
17. The highest exposure level represented approximately 50% of
the Lower Explosive Limit of each test material. On GD 18, animals
were sacriﬁced and evaluated as described in Section 2.1.6.2.1.5. Administration of test substance and exposure schedule
The experimental and control animals were placed into whole-
body inhalation chambers operated under dynamic conditions for
at least 6 h per day for GD 5–16 at 2000, 10,000, and 20,000mg/m3,
or for GD 5–10 at 30,000 mg/m3 after target exposure levels were
reached. The animals remained in the chambers for at least an
additional 23 min (theoretical equilibration time) while the test
atmosphere cleared. Females were exposed in 1.0 m3 stainless
steel and glass chambers operated at a ﬂow rate of approximately
12–15 air changes/hour. During exposure periods, animals were
individually housed in stainless steel, wire mesh cages. Flow rate
and slightly negative pressure was monitored continuously and
recorded approximately every 30 min. Light (ca. 30–40 foot-
candles 1.0 m above the ﬂoor) and noise levels (<85 db) in the
exposure room were measured pretest and at the beginning,
middle and end of the study. Oxygen levels in the exposure
chambers were maintained between 20.6 and 20.7%.
The control group was exposed to clean ﬁltered air under con-
ditions identical to those used for groups exposed to the test sub-
stance. The test substance was administered fully vaporized in the
breathing air of the animals. The chamber concentrations were
measured in the breathing zone of the mice by on-line gas chroma-
tography (GC). The chromatographic analyses were used to assess
the stability of the test substance over the duration of the study.
Additionally, sorbent tube samples were collected once weekly
and stored in a freezer for analysis by a detailed capillary GC
method to compare component proportions of the test material
atmosphere with the liquid test material. Homogeneity of the
exposure systemwas validated prior to the start of each study. Par-
ticle size determination conﬁrmed that exposures were to vapor
only (see Section 3.1).
2.1.6. Experimental evaluation
Animals were examined for viability at least twice daily during
the study. Body weights were recorded prior to selection and on
GD 0, 5, 8, 11, 14, 17, and 18. Food consumption was measured
for mated females on GD 5, 8, 11, 14, 17, and 18. A clinical exam-
ination of each female occurred prior to selection and daily during
gestation. Additionally, group observations of the animals for mor-
tality and obvious toxic signs while in the chambers were recorded
at 15, 30, 45, and 60 min after initiation of the exposure and then
hourly during each exposure.
Body weights were recorded on GD 18, the day of necropsy.
Dams were sacriﬁced by CO2 asphyxiation followed by exsanguina-
tion. A gross necropsy was performed on all conﬁrmed-mated
females. Uterine weights with ovaries attached were recorded at
the time of necropsy. Uterine contents were examined and the
numbers and locations of implantation sites, early and late resorp-
tions, and live and dead (live or dead in utero) fetuses were
counted. Ovarian corpora lutea also were counted. The uteri of all
apparently non-pregnant females were stained with 10% ammo-
nium sulﬁde to conﬁrm non-pregnancy status. Evaluations of dams
during cesarean section and subsequent fetal evaluations were
conducted without knowledge of treatment group in order to min-
imize bias. Each fetus was weighed and examined externally for
gross malformations and variations. Fetal sex was determined by
external examination and conﬁrmed internally only on those
fetuses receiving visceral examinations. Fetuses were euthanized
by hypothermia after the external examination and weighing.
The viscera of approximately one-half of the fetuses of each lit-
ter were examined by fresh dissection (Staples, 1974; Stuckhardt
and Poppe, 1984) prior to decapitation of the fetus. The heads were
preserved in Bouin’s solution for at least two weeks, then rinsed
and subsequently stored in 70% ethanol. Free-hand razor blade sec-
tions of the Bouin’s-ﬁxed fetal heads were examined for the pres-
ence of abnormalities. The remaining fetuses were eviscerated,
Table 1
Experimental Design.
Study BGVC, G/MTBE-1 G/MTBE-2
Laboratory EMBSI (NJ) HLS – RTI (NJ – NC)
Species/strain/source VAF Crl:CD-1(ICR)BR; Charles River MI VAF Crl:CD-1(ICR)BR; Charles River NC
Test substance BGVC G/MTBE G/MTBE
Wt./Age at mating 25–33 g;11–12 wk 26–35 g; 12–13 wk 20–35 g; 9–11 wk
Exposure levels [mg/m3] 0 2,000 10,000 20,000 0 2,000 10,000 20,000 30,000
Number of females 25 25 25 25 23 23 23 23 38
Exposure days [6 h/d] GD 5–17 GD 5–16 GD 5–10
Necropsy GD 18 GD 17
Body weights GD 0, 5, 8, 11, 14, 17 and 18 GD 0 and daily GD 5–17
Food consumption GD 0, 5, 8, 11, 14, 17 and 18 GD 0 and daily GD 5–17
Maternal organ weights Liver, paired kidney and adrenal weights
Fetal weight/external observations 100% 100%
Skeletal/visceral observations 50% examined Not done
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examined for bone and cartilage development and any abnormali-
ties. The fetal skeletons were preserved in glycerine with thymol
after they were processed and stained.2.1.7. Statistical analysis
Statistical methods included evaluation of equality of means by
appropriate one-way analysis of variance and a test for ordered
response in the dose groups. Bartlett’s Test was performed to
determine if the dose groups had equal variance followed by stan-
dard one-way analysis of variance (Snedecor and Cochran, 1989)
after which parametric methods were employed when variances
were equal. For continuous data, percentages were calculated
and transformed by Cochran’s transformation, followed by the
arc sine transformation (Snedecor and Cochran, 1989). The raw
percentages and the transformed percentages were both tested
for statistical signiﬁcance.
For the parametric procedures, a standard one-way ANOVA
using the F distribution to assess signiﬁcance was used (Snedecor
and Cochran, 1989) followed by Dunnett’s Test if signiﬁcant differ-
ences in ANOVA were found (Dunnett, 1964). A standard regres-
sion analysis for linear response in the dose groups was
performed, which also tested for linear lack of ﬁt in the model.
For the nonparametric procedures, equality of means was
assessed by the Kruskal–Wallis Test (Hollander and Wolfe, 1973)
followed by Dunn’s Summed Rank Test (Hollander and Wolfe,
1973), if needed. Jonckheere’s Test for monotonic trend in the dose
response was also performed (Hollander and Wolfe, 1973). Bart-
lett’s Test for equal variance was conducted at the 1% level of sig-
niﬁcance. All other tests were conducted at the 5% and 1% level of
signiﬁcance. Data for non-pregnant females, dams delivering
before GD 18, or from pups which were delivered early in those lit-
ters were not included in analyses.
Means and standard deviations were calculated for animal,
exposure and chamber environmental data. Body weight change
and food consumption were evaluated for individual intervals
and also for the pre-exposure, exposure, and post-exposure peri-
ods. The coefﬁcient of variation was calculated when considered
relevant. Fetal body weight was analyzed by a mixed model anal-
ysis of variance using the litter as the basis for analysis and the lit-
ter size as a covariate. The analysis of anomalies (malformations or
variations) was based on a generalized estimating equation (GEE)
application of the linearized model, Ryan (1992). The model used
the litter as the basis for analysis and considered correlation
among littermates by incorporating an estimated constant correla-
tion and the litter size as a covariate. If the overall effect of dose, or
the dose by sex effect was statistically signiﬁcant, the dose group
means were tested pairwise against the control group using least
squares means which accounted for differences in litter size andsex. The mathematical model was based on a method by Chen et.
al (1996). The analysis was run using SAS (Little, et. al, 1997).
In addition to the speciﬁc anomalies, a series of combined anal-
yses were performed within each category as applicable. These
combined categories were: Combined Malformations and Varia-
tions for All Fetuses; for Live Fetuses; for Dead Fetuses; Malforma-
tions for All Fetuses; for Live Fetuses; for Dead Fetuses; and
Variations for Live Fetuses; and for Dead Fetuses.
2.2. Second G/MTBE study
2.2.1. Experimental design
The repeat of the G/MTBE study at HLS-RTI was similar to the
studies conducted at EMBSI with the exceptions summarized in
Table 1. The same strain of mouse was used but was obtained from
Charles River Laboratories in Raleigh, NC. An additional 30,000 mg/
m3 exposure group of 38 females was added to the study design.
The exposure period for the ﬁrst four exposure groups was 6 h/
day from GD 5–16. The 30,000 mg/m3 group was exposed from
GD 5–10 since the speciﬁc malformations observed in the original
G/MTBE study (ventral wall defects) are formed early in the gesta-
tion period (GD 7–9; Rugh, 1968). On GD 11–16, females in the
30,000 mg/m3 exposure group were removed from their home
cage and placed in another suspended cage without feed to match
as closely as possible the housing conditions of Group 1–4 females
for the 6-h exposure period. They were then returned to their
home cage at the same time as the exposed females. At sacriﬁce,
the liver, paired adrenal glands, and paired kidneys of each plug-
positive female were weighed. Fetal body weights were measured
and all fetuses were examined for external anomalies, but neither
visceral nor skeletal observations were conducted (Table 1).
2.2.2. Second study statistics
The unit of comparison was the pregnant female or litter. Quan-
titative continuous data (e.g., body weights, etc.) were compared
among the 4 treatment groups and 1 vehicle control group using
either parametric ANOVA under the standard assumptions or
robust regression methods (Zeger and Liang, 1986; Royall, 1986;
Huber, 1967), which do not assume homogeneity of variance or
normality. If the ANOVA test was statistically signiﬁcant, then sta-
tistical pairwise comparisons were made (see below). The homoge-
neity of variance assumption was examined via Levene’s Test
(Levene, 1960). If Levene’s Test indicated lack of homogeneity of
variance (p < 0.05), robust regression methods (heterogeneous var-
iance methods) were used to test all treatment effects. Overall
treatment group differences were tested by Wald Chi-Square Tests
followed by individual tests for exposed vs. control group compar-
isons when the overall treatment effect was signiﬁcant. The pres-
ence of linear trends was analyzed by robust regression methods
Table 3
Concentration of major hydrocarbons measured in test substance supplied to
laboratories.
Hydrocarbon concentration (area percent)a
BGVC G/MTBE
Isobutane 3.6 2.2
n-butane 15.2 11.1
Isopentane 35.1 31.0
n-pentane 13.2 9.1
trans-2-pentene 2.5 2.0
2-methyl-2-butene 3.8 2.9
2,3-dimethylbutane 1.6 0.9
2-methylpentane 6.3 4.5
3-methylpentane 3.6 2.6
n-hexane 3.0 2.1
Methylcyclopentane 1.5 1.1
2,4-dimethylpentane 1.0 0.9
Benzene 2.1 1.5
2-methylhexane 1.1 1.0
2,3-dimethylpentane 1.1 1.0
3-methylhexane 1.3 1.1
Isooctane 1.3 1.2
Toluene 3.0 2.5
MTBE 0.0 21.3
a Values for these 18 reference hydrocarbons were derived pre-study (Henley
et al., 2014). A total of 131 peaks were separated and identiﬁed for the BGVC study.
The reference hydrocarbons comprised over 81% of the total mass but are
normalized to 100% to enable comparisons across the three labs.
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Analytical methods when variances were homogeneous were
similar to those employed in the EMBSI studies. For the litter-
derived percentage data, the ANOVAwas weighted according to lit-
ter size. The presence of linear trends was analyzed by GLM proce-
dures for homogenous data (SAS Institute Inc., 1999a,b,c,d,e, 2000,
2001).
Nominal scale measures were analyzed by Chi-Square Test for
Independence for differences among treatment groups (Snedecor
and Cochran, 1989) and by the Cochran–Armitage Test for Linear
Trend on Proportions (Cochran, 1954; Armitage, 1955; Agresti,
1990), followed by a Fisher’s Exact Probability Test, with appropri-
ate adjustments for multiple comparisons, if Chi Square results
were signiﬁcant.
A test for statistical outliers (SAS Institute Inc., 1999b) was per-
formed on female body weights, feed consumption (in g/day), and
selected organ weights. Body weight change and food consumption
were evaluated for individual intervals and also for the pre-expo-
sure, exposure, and post-exposure periods. If examination of perti-
nent study data did not provide a plausible, biologically sound
reason for inclusion of the data ﬂagged as ‘‘outlier,’’ then the data
were excluded from summarization and analysis and designated
as outliers. Unless otherwise speciﬁed, the level of signiﬁcance
used for the various tests was p < 0.05.2.3. Compliance
All studies were conducted to meet/exceed compliance with the
EPA’s guidelines and standards for the conduct of inhalation expo-
sures and developmental toxicity (US EPA 1994a, 1994b, 1996,
1998), with OECD guidelines for chemical testing (OECD, 2001),
and with provisions of the Animal Welfare Act (Code of Federal
Regulations, 1966) and the National Research Council’s Guide for
the Care and Use of Laboratory Animals (NRC, 1996).3. Results
3.1. Exposure monitoring
Chamber distribution analyses conducted by the laboratory
during the conduct of the studies showed that the test substances
were evenly distributed within the exposure chambers. The mean
measured concentrations (analytical and nominal) were reason-
ably close to the targeted exposure levels for each of the gasoline
oxygenate studies Table 2.
The concentrations of themajor components in the testmaterials
supplied for the studies as reported by Henley et al. (2014) are
shown in Table 3. The values are expressed as area percent to
facilitate comparisonbetween studies. Analysis of themajor compo-Table 2
Total hydrocarbon concentrations measured in exposure chambers.
Chamber concentrations (mg/m3)a
Target Actual (mean ± SD)
BGVC G/MTBE-1 G/MTBE-2
2000 Analytical 2086 ± 175 2122 ± 57 2074 ± 248
10,000 Analytical 10,625 ± 358 10,788 ± 322 9899 ± 700
20,000 Analytical 20,903 ± 600 20,741 ± 923 20,297 ± 1815
30,000 Analytical n/a n/a 29,259 ± 1480
Average MWb 73.8 73.7 73.7
a Total hydrocarbon concentrations as determined by gas chromatography
(infrared spectroscopy for G/MTBE-2).
b Average molecular weight of hydrocarbons in condensate samples.nents in the exposure chamber samplesmeasuredby the lab showed
a close comparison between the neat test substance and the vapor-
ized test substance. The averagemolecularweights of the hydrocar-
bons in the condensate test materials shown in Table 2 can be used
to calculate the approximate part-per-million concentrations.
In the BGVC study, particles sized at 0.26 mg/m3 in the control
chamber and 0.20 mg/m3 in the 20,000 mg/m3 chamber were mea-
sured. These particles were judged to be ambient background par-
ticles (e.g., animal dander) and not from the generation of the test
substance. No particles were detected in the G/MTBE or G/MTBE-2
study chambers.
3.2. Clinical in-life observations and survival
All BGVC- and G/MTBE-exposed dams were free of clinical or
postmortem effects attributable to treatment. One control, one
10,000 mg/m3 target, and two 20,000 mg/m3 target dams in the
BGVC study were determined at the scheduled terminal sacriﬁce
to be not pregnant, and one control and one 20,000 mg/m3 target
dam delivered their litters prior to their scheduled sacriﬁce. In
the G/MTBE study, one control dam, one dam exposed at
2,000 mg/m3 and three exposed at 20,000 mg/m3 were not preg-
nant at the scheduled terminal sacriﬁce. Additionally, one control
dam, one dam exposed at 2,000 mg/m3 and two exposed at
20,000 mg/m3 delivered all or part of their litters prior to the
scheduled sacriﬁce. In the repeat G/MTBE study (G/MTBE-2), one
female was removed from study due to a pre-existing condition.
There were no clinical signs indicative of exposure-induced mater-
nal toxicity during the studies, except for slight emaciation noted
in one dam at 20,000 mg/m3 BGVC dam (19% body weight loss,
GD 8–11). In addition, labored breathing was observed in the
G/MTBE-2 study on GD 9 post exposure in one dam at
20,000 mg/m3 and on GD 10 post exposure for one dam at
30,000 mg/m3.
3.3. Gestational body weight
In the BGVC study, maternal toxicity at 20,000 mg/m3 was evi-
dent as statistically signiﬁcant decreases in mean gestational body
weight from GD 11 onward, and mean gestational body weight
Table 4
Effects of BGVC and G/MTBE on maternal body weight.
BGVC G/MTBE
Concentration (mg/m3) 0 20,000 0 20,000
N 23 21 24 20
Gestation day Mean gestation body weight (g) ± SD
0 30.7 ± 2.3 30.3 ± 1.7 28.9 ± 1.4 28.7 ± 1.3
5 33.3 ± 1.8 33.0 ± 1.7 31.6 ± 1.9 31.3 ± 1.4
8 35.2 ± 2.3 34.2 ± 1.6 33.5 ± 2.0 33.1 ± 1.3
11 39.5 ± 2.4 37.2 ± 2.4* 37.8 ± 2.4 37.1 ± 1.5
14 46.7 ± 3.2 43.5 ± 3.2* 44.5 ± 2.9 43.7 ± 2.1
17 56.5 ± 4.9 52.1 ± 4.5* 53.0 ± 3.5 52.8 ± 2.7
18 59.0 ± 5.5 54.3 ± 4.9* 55.5 ± 4.0 54.9 ± 3.1
18C 36.0 ± 2.7 35.2 ± 1.7 34.7 ± 2.1 34.5 ± 2.3
Uterus weight 23.0 ± 3.3 19.1 ± 4.0** 20.8 ± 2.8 20.4 ± 2.2
Mean gestation body weight change (g) ± SD
0–5 2.7 ± 1.5 2.7 ± 1.3 2.7 ± 1.0 2.6 ± 1.2
5–8 1.9 ± 0.9 1.2 ± 0.7 1.9 ± 1.0 1.9 ± 0.7
8–11 4.3 ± 0.9 3.0 ± 1.3** 4.2 ± 1.3 4.0 ± 1.0
11–14 7.2 ± 1.3 6.3 ± 1.3 6.8 ± 1.3 6.6 ± 1.4
14–17 9.8 ± 2.0 8.6 ± 2.0 8.5 ± 1.4 9.1 ± 1.0
17–18 2.5 ± 1.3 2.2 ± 1.0 2.5 ± 1.0 2.2 ± 0.8
5–18 25.7 ± 4.4 21.4 ± 3.8** 23.8 ± 3.0 23.7 ± 2.8
0–18 28.4 ± 4.8 24.0 ± 4.1** 26.5 ± 3.4 26.3 ± 2.8
0–18C 5.3 ± 2.6 5.0 ± 2.0 5.8 ± 1.9 5.9 ± 1.9
C = terminal body weight minus gravid uterine weight at necropsy.
* P < 0.05 Dunnett’s test.
** P < 0.01 Dunnett’s test.
Table 5a
Effects on maternal body weight and food consumption in G/MTBE-2 study.
Concentration (mg/m3) 0 20,000 30,000
N 23 23 36
Gestation day Mean gestation body weight (g)
0 26.7 ± 0.4 27.3 ± 0.3 27.5 ± 0.2
5 27.6 ± 0.4 28.5 ± 0.3 27.5 ± 0.2
8 29.2 ± 0.4 30.0 ± 0.3 29.8 ± 0.3
11 32.8 ± 0.5 33.2 ± 0.5 33.0 ± 0.5
14 39.2 ± 0.6 38.7 ± 0.9 39.7 ± 0.7
17 48.4 ± 0.7 46.7 ± 1.4 48.3 ± 1.2
Mean gestation body weight change (g)
0–5 0.8 ± 0.2 1.2 ± 0.2 0.8 ± 0.2
7–8 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1
12–13 2.1 ± 0.1 1.5 ± 0.2** 2.0 ± 0.1
16–17 3.2 ± 0.2 2.7 ± 0.2 3.1 ± 0.1
5–10 3.3 ± 0.2 NC 3.0 ± 0.2
5–16 17.6 ± 0.4 15.5 ± 1.2 NC
10–17 17.5 ± 0.4 NC 17.0 ± 0.9
Gestation change 20.4 ± 0.6 18.6 ± 1.5 20.0 ± 1.1
Uterus weight (g) 17.3 ± 0.5 15.7 ± 1.2 16.8 ± 0.9
Gestation change corrected 3.1 ± 0.3 2.9 ± 0.4 3.2 ± 0.3
Mean gestation food consumption (g)
0–5 6.1 ± 0.2 5.3 ± 0.2 6.8 ± 0.4
7–8 7.0 ± 0.4 6.2 ± 0.2 6.4 ± 0.2
12–13 7.1 ± 0.2 6.9 ± 0.2 7.8 ± 0.2
16–17 7.6 ± 0.2 7.3 ± 0.2 7.5 ± 0.2
5–10 6.9 ± 0.4 NC 6.2 ± 0.1
5–16 6.9 ± 0.2 6.8 ± 0.3 NC
10–17 7.3 ± 0.2 NC 7.6 ± 0.2
0–17 6.5 ± 0.1 6.1 ± 0.2 6.9 ± 0.2
NC = not calculated due to differences in exposure duration between 30,000 mg/m3
and other exposure groups. Gestation change = total body weight change during
gestation. Gestation corrected = body weight change during gestation minus gravid
uterine weight.
** P < 0.01 Dunnett’s test.
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signiﬁcant differences were not evident at 2,000 or 10,000 mg/
m3. In the G/MTBE study, there were no statistically signiﬁcant dif-
ferences in the mean gestational body weight, mean gestational
body weight change, or mean uterine weights between treated
and control dams at any interval during gestation (Table 4).In the G/MTBE-2 study, there was a decreased daily maternal
body weight change only for GD 12–13 interval at the 2000 and
20,000 mg/m3 dose levels (Table 5). These decreases were consid-
ered incidental since they only occurred once and did not display a
dose–response pattern. Maternal gestational weight change (gesta-
tional body weight gain minus gravid uterine weight) was unaf-
fected across all groups.
In the G/MTBE-2 study, maternal absolute gravid uterine
weight, paired adrenal gland weight, and paired kidney weight
were unaffected across all groups (Table 5b). Maternal paired adre-
nal gland and paired kidney weights (relative to terminal body
weights) were equivalent across all groups (not shown). Maternal
absolute liver weights were equivalent at 0, 2000, 20,000, and
30,000 mg/m3 but were signiﬁcantly increased (11%; p < 0.05) at
10,000 mg/m3. Relative (to terminal body weight) maternal liver
weights were signiﬁcantly increased in a concentration-related
manner at 2000 (6%; p < 0.01), 10,000 (11%; p < 0.001), and
20,000 (11%; p < 0.001) mg/m3, in dams exposed through GD-16;
relative liver weight was unaffected at 30,000 mg/m3, where expo-
sures ended on GD 10.
3.4. Gestational food consumption
Exposure to BGVC produced no statistically signiﬁcant differ-
ences in mean gestational food consumption between treated
and control dams at any interval during the gestation period. Sim-
ilarly, exposure to G/MTBE produced no effects upon food con-
sumption in either the original or repeated studies.
3.5. Gross postmortem observations
All BGVC-exposed dams were free of grossly observable abnor-
malities at the gross postmortem examination. In G/MTBE exposed
dams, the only gross observation was red contents in the stomach
of a dam that had delivered her litter. Additionally, the fetus closest
to the cervix in one of the uterine horns of a control damwas found
partially in the body of the uterus. This was apparently the begin-
ning of her delivery. As the fetus had not delivered, the dam and
litter were treated as a terminal sacriﬁce and not a delivered litter.
All other dams exposed to G/MTBE and G/MTBE-2 had no grossly
observed abnormalities.
3.6. Uterine implantation data
Table 6 presents the number of ovarian corpora lutea, uterine
implantation sites, live fetuses per litter, and resorption data for
dams exposed in the three studies. The uterine implantation data
for BGVC exposed dams revealed a statistically signiﬁcant decrease
in the mean number of live fetuses in the 20,000 mg/m3 target
group (11.0 per litter vs. 13.6 in the control group). Live litter size
is a consequence of the number of eggs ovulated (measured by the
corpora lutea in the ovaries), implantation success (assessed as
pre-implantation loss), and viability of the embryo/fetus (post-
implantation loss, identiﬁed as early or late resorptions or dead
fetuses). The statistically signiﬁcant decrease in mean live litter
size was due to both a lower value for ovarian corpora lutea, which
occurred before exposure, and a higher incidence of implantation
site resorptions, which occurred after exposure was initiated. The
mean number of corpora lutea per litter at 20,000 mg/m3 was 1.7
less in the 20,000 mg/m3 BGVC group than that observed in the
control group. During pregnancy, the numbers of ovarian corpora
lutea are established when the eggs are ovulated from the ovary,
prior to the day of pregnancy when exposures to the test material
began. Based upon the ratio of implantations to ovarian corpora
lutea, the overall implantation success rate was greater than 95%
for both groups. The difference in the mean number of corpora
Table 5b
Absolute and relative organ weights of mice in G/MTBE-2 study.
Gasoline/MTBE vapor condensate (mg/m3 inhaled)
0a 2,000a 10,000a 20,000a 30,000b
No. of mice 23 22 19 22 36
Terminal body wt (g) at GD 17 47.1 ± 0.7 46.7 ± 1.5 47.5 ± 0.8 45.9 ± 1.4 47.4 ± 1.2
Gravid uterine Wt (g) 17.3 ± 0.5 15.6 ± 1.1 16.6 ± 0.4 15.7 ± 1.2 16.8 ± 0.9
Liver wtc
Absolute (g) 2.45 ± 0.05 2.58 ± 0.09 2.72 ± 0.05⁄ 2.63 ± 0.07 2.43 ± 0.06
Relatived 5.20 ± 0.06 5.53 ± 0.09⁄⁄⁄ 5.74 ± 0.09 5.76 ± 0.07⁄⁄⁄ 5.15 ± 0.09
Paired adrenal wt:c
Absolute (g) 0.014 ± 0.001 0.014 ± 0.001 0.013 ± 0.00e 0.014 ± 0.001 0.014 ± 0.00
Relatived 0.029 ± 0.001 0.031 ± 0.002 0.028 ± 0.001e 0.031 ± 0.002 0.030 ± 0.002
Paired kidney wtc
Absolute (g) 0.428 ± 0.009 0.445 ± 0.011 0.439 ± 0.005 0.438 ± 0.009 0.431 ± 0.007
Relatived 0.907 ± 0.011 0.978 ± 0.045 0.928 ± 0.016 0.982 ± 0.050 0.935 ± 0.034
⁄p < 0.05 Dunnett’s test.
⁄⁄p < 01 and ⁄⁄⁄p < 0.001 Individual t-test in robust regression model.
a Exposure GD 5–16.
b Exposure GD 5–10.
c Includes all pregnant dams until terminal sacriﬁce on GD 17. Reported as mean ± SEM.
d Relative = % sacriﬁce body weight.
e Paired adrenals 10,000 mg/m3; N = 18 due to exclusion of one mouse as a statistical outlier.
Table 6
Uterine data.
Uterine data (mean + SD)
Endpoint Exposure group mg/m3
No. of litters 0 2,000 10,000 20,000 30,000
BGVC 23a 25 24 22a n/a
G/MTBE 24a 20a 25 20b n/a
G/MTBE-2 23 22 19 22 36
Corpora lutea per dam
BGVC 14.6 ± 2.4 14.6 ± 2.6 14.7 ± 2.4 12.9 ± 2.6 n/a
G/MTBE 14.0 ± 1.7 13.4 ± 2.2 13.5 ± 3.0 13.5 ± 2.5 n/a
G/MTBE-2 13.0 ± 0.4 12.2 ± 0.6 12.8 ± 0.4 13.2 ± 0.6 13.2 ± 0.5
Implantation sites per litter
BGVC 14.1 ± 2.1 14.2 ± 2.7 14.0 ± 2.9 12.4 ± 2.6 n/a
G/MTBE 13.5 ± 1.5 13.2 ± 2.4 12.9 ± 3.4 13.3 ± 2.0 n/a
G/MTBE-2 12.7 ± 0.4 12.0 ± 0.6 12.7 ± 0.3 13.2 ± 0.5 12.9 ± 0.4
Total live fetuses per litter
BGVC 13.6 ± 2.1 13.5 ± 2.7 13.3 ± 3.0 11.0* ± 3.7 n/a
G/MTBE 12.4 ± 2.0 12.6 ± 2.3 12.1 ± 3.2 12.8 ± 1.9 n/a
G/MTBE-2 12.0 ± 0.4 11.2 ± 0.7 11.8 ± 0.3 12.6 ± 0.5 12.3 ± 0.3
Resorptions per litter
BGVC 0.4 ± 0.8 0.6 + 0.7 0.5 ± 1.1 1.3*,c,d ± 3.1 n/a
G/MTBE 1.1 ± 1.1 0.6 ± 1.0 0.6 ± 1.0 0.6 ± 0.6 n/a
G/MTBE-2 0.6 ± 0.2 1.3 ± 0.5 0.7 ± 0.2 1.7 ± 0.9 1.6 ± 0.5
Fully resorbed litters
BGVC 0/24 0/25 0/24 1/23 n/a
G/MTBE 0/24 0/21 0/25 0/22 n/a
G/MTBE-2 0/23 1/22 0/19 2/22 3/36
BGVC – baseline gasoline vapor condensate exposure.
G/MTBE – gasoline combined with MTBE vapor condensate exposure.
G/MTBE-2 – repeat of G/MTBE study.
* p < 0.05.
a 1 additional litter delivered prior to scheduled necropsy.
b 2 additional litters delivered prior to scheduled necropsy.
c contained 1 female with unexplained emaciation, GD 11.
d statistically signiﬁcant as resorptions/implantation following arc sine
transformation.
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the mean number of live fetuses per litter (due to the decreased
numbers of eggs ovulated, and subsequently the number of ovarian
corpora lutea present). Additionally, the incidence of resorptions,
which was statistically signiﬁcantly higher than in the control
group (1.3 per litter vs. 0.4 in the control group), also contributed
to the decrease in live litter size. The ratio of live fetuses per
implantation sites was not statistically different between the con-
trol and high-exposure groups. The statistically signiﬁcantdecrease in the number of live fetuses per litter was considered
to be partly treatment-related.
Exposure to BGVC appeared to cause an increase in resorptions
at 20,000 mg/m3. The difference was not statistically signiﬁcant as
a mean value per litter, but reached statistical signiﬁcance
(p < 0.05) when analyzed as a transformed ratio of resorptions/
implantations. This parameter was strongly inﬂuenced by a single
animal in the high-exposure group with complete litter resorption.
This animal was noted to be emaciated during mid-gestation, los-
ing a total of 9 g of body weight (25% of her weight) between GD 5–
11. This weight loss was greater than could be accounted for by
loss of the developing embryos. Although this animal was not con-
sidered an outlier, the data were reanalyzed to determine the
potential impact of excluding this litter from the statistical analy-
sis. When her data were removed from the data set, statistical sig-
niﬁcance disappeared for resorption parameters, but live litter size
remained statistically different than control.
There were no other statistically signiﬁcant differences between
the control group and BGVC treated dams for the other implanta-
tion parameters. In both the G/MTBE and G/MTBE-2 studies, there
were no statistically signiﬁcant differences in the implantation
parameters between the control and treated dams (Table 6),
although 8.3% and 9.1% of litters were fully resorbed in the
30,000 and 20,000 mg/m3 exposure groups, respectively.
There were 0, 1 (4.5%), 0, 2 (9.1%), and 3 (8.3%) fully resorbed
litters (100% resorptions) in the G/MTBE-2 study at 0, 2000,
10,000, 20,000, and 30,000 mg/m3, respectively (Table 6). These
ﬁndings did not differ statistically across groups but the slightly
higher numbers of fully resorbed litters may be an indication of
maternal stress in some of the pregnant animals at 20,000 and
30,000 mg/m3.3.7. Fetal body weight
The mean fetal weights and litter weights are presented in
Table 7. There was a statistically signiﬁcant difference in the mean
fetal body weight among the BGVC dose groups based on a mixed
model analysis of variance that considered dose group, litter size,
and fetal sex as explanatory values. The mean fetal body weight
of the 20,000 mg/m3 target group and the 10,000 mg/m3 target
group were statistically signiﬁcantly lower than the control fetal
weight based on a pair-wise comparison using least square means.
There were no statistically signiﬁcant differences in the mean fetal
Table 7
Fetal body weights.
Average fetal body weight/litter (g)
Exposure concentration (mg/m3)
Study 0 2,000 10,000 20,000 30,000a
EMBSIb Mean and least squares mean, males and females combined
BGVC mean 1.32 1.29 1.25 1.26 N/A
Least squares mean 1.32 1.30 1.26* 1.23** N/A
G/MTBE Mean ± standard deviation
Males 1.33 ± 0.10 1.33 ± 0.11 1.34 ± 0.12 1.27 ± 0.12 N/A
Females 1.29 ± 0.09 1.29 ± 0.11 1.29 ± 0.13 1.22 ± 0.11 N/A
HLS-RTIc Mean ± standard deviation
G/MTBE-2 1.00 ± 0.02 1.01 ± 0.02 0.95 ± 0.02 0.95 ± 0.03 1.02 ± 0.02
a Exposures conducted GD 5–7.
b Exposure conducted GD 5–17; weights on GD-18.
c All but 30,000 mg/m3 exposures conducted at GD 5–16; weights on GD-17.
* p < 0.05.
** p < 0.01.
Table 8
Incidence of total variations and malformations in control and high dose groups.
Variations and malformationsa Test substances and concentration (mg/m3)
BGVCb G/MTBEb G/MTBE-2c
0 20,000 0 20,000 0 20,000 30,000
External variations
Fetuses 0/313 0/242 0/297 0/255 3/276 3/252 0/407
Litters 0/23 0/21 0/24 0/20 3/23 3/20 0/33
External malformations
Fetuses 2/313 2/242 6/297 6/255 2/276 1/252 7/407
Litters 2/23 2/21 5/24 6/20 2/23 1/20 4/33
Visceral variations
Fetuses 4/155 11/122 4/150 4/129 Not Determined
Litters 3/23 8/21 4/24 3/20
Visceral malformations
Fetuses 2/155 0/122 0/150 0/129
Litters 2/23 0/21 0/24 0/20
Skeletal variations
Fetuses 80/158 83/120 84/147 67/126
Litters 21/23 20/21 21/24 17/20
Skeletal malformations
Fetuses 0/158 1/120 2/147 1/126
Litters 0/23 1/21 2/24 1/20
a Fetuses: number of observations per number of fetuses examined; Litters: number of litters with observations.
b Exposures were from gestation day 5–17.
c Exposures were from gestation day 5–16 for 20,000 mg/m3 group and 5–10 for 30,000 mg/m3 group.
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3.8. Fetal external observations
The summary incidences of fetuses, for fetal variations, and for
litters with malformations or structural variations are shown in
Table 8. External observations were minimal in the BGVC exposed
animals and there were no statistically signiﬁcant differences with
control treated animals for either the total numbers of litters with
malformed fetuses, fetal variations, or for individual defects
(Table 8). One dead fetus in the 20,000 mg/m3 target concentration
group had the following observations: open eye, spina biﬁda,
curled tail, exencephaly, cranioschisis, and polyhydramnios (red).
The observations for fetal neural tube closure defects for this fetus
(exencephaly, cranioschisis, spina biﬁda) were combined for statis-
tical analysis, and there were no statistical differences between
groups.
In the G/MTBE study, there also were no statistically signiﬁcant
differences in external variations or malformations between the
control and treated groups. Ectopia cordis and gastroschisis were
observed in two fetuses of the same litter in the 10,000 mg/m3group (Table 9). Microstomia and misshapen nose were also
observed in one dead fetus in the 10,000 mg/m3 group, and
micromelia and syndactyly were seen in one dead fetus in the
10,000 mg/m3 group.
In the G/MTBE-2 study, there were no statistically signiﬁcant
differences across groups (Table 8). The fetal external malforma-
tions included encephalocele in one fetus at 2000 mg/m3 and gas-
troschisis in one fetus at 30,000 mg/m3. Cleft palate was observed
in two fetuses (2 litters) in the control group, one fetus each in the
2000, 10,000, 20,000 mg/m3 groups and in 7 fetuses (4 litters) in
the 30,000 mg/m3 (Table 9). This apparent (non-statistically signif-
icant) increase in the fetal (and litter) incidence of cleft palate at
30,000 mg/m3 may be indirect evidence of maternal stress during
exposures at this high concentration. Physical stressors such as
restraint as well as corticosteroid stress hormones are well-estab-
lished inducers of cleft palate in mice (Fraser and Fainstat, 1951;
Lee et al., 2008).
3.9. Fetal visceral observations
There were no statistically signiﬁcant differences in the
incidence of visceral observations between the control and BGVC
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arising from the left side of the urinary bladder, dilated renal pel-
vis, retinal fold, and misshapen cerebra (indentation in the cere-
bra). There were no fetuses with multiple visceral observations.
There were also no statistically signiﬁcant differences in the inci-
dence of visceral observations between the control and G/MTBE
treated groups. In the 10,000 mg/m3 group, the two fetuses with
ectopia cordis also had elongated pulmonary trunks with either a
narrowing of the pulmonary trunk or an enlarged atrium.3.10. Fetal skeletal observations
There were no statistically signiﬁcant differences in the inci-
dence of skeletal observations between the control and BGVC-trea-
ted groups (Table 8). Hypoplastic supraoccipital bones, hypoplastic
sternebrae, rudimentary ossiﬁcation site in the sternum, and ossi-
ﬁed calcaneus were the most frequently noted skeletal observa-
tions. Ossiﬁcation of the calcaneus, which was observed in the
majority of the fetuses is an indication of slightly advanced devel-
opment and is considered normal. The skeletal variations observed
are common in mice and are considered unrelated to exposures.
There were also no statistically signiﬁcant differences between
groups when related skeletal observations were combined for
analysis.
There were no statistically signiﬁcant differences in the inci-
dence of skeletal observations between the control and G/MTBE
treated groups.4. Discussion
Maternal toxicity was observed after exposure to the baseline
gasoline vapor condensates (BGVC). BGVC exposures resulted in
slightly but statistically signiﬁcant reduced gestational body
weights and gestational body weight changes in the 20,000 mg/
m3 target group. BGVC exposure at similar concentrations did not
affect gestational body weights in a companion developmental
toxicity study in rats (Roberts et al., 2014); however a two-gener-
ation reproductive toxicity study in rats demonstrated decreased
body weight gains in P0 and F1 males exposed to 20,000 mg/m3
for a longer duration (Gray et al., 2014). Labored breathing was
observed in animals of the 20,000 mg/m3 and 30,000 mg/m3 expo-
sure group in the G/MTBE-2 study.
Statistically signiﬁcant reduced fetal body weights, compared
with the control fetal weights, were also noted in the 10,000 and
20,000 mg/m3 BGVC exposure groups. This reduction in average
fetal body weight was similar at both dose levels, at approximately
95% of control values. The reduction of these fetal weights occurred
concurrently with decreased maternal body weight at 20,000 mg/m3
but there were no statistically signiﬁcant reductions in maternal
body weight and body weight changes in the 10,000 mg/m3 target
concentration group. In the G/MTBE studies, in which BGVC
comprised 80% of the test material, fetal body weights at
20,000 mg/m3 were also 95–96% of control values but not statisti-
cally signiﬁcantly lower. A 5% decrease in fetal body weight is at
the margin of the statistical power to detect a decrease in a study
of this size in mice. In companion developmental and two-genera-
tion reproductive toxicity studies in rats, exposure to BGVC did not
affect fetal body weights (Roberts et al., 2014; Gray et al., 2014).
The number of live fetuses per litter was statistically signiﬁ-
cantly reduced in the 20,000 mg/m3 BGVC target group. The num-
bers of implantation sites and ovarian corpora lutea were
substantially lower in this group than in the control and the
other treatment groups, but statistical analysis of the number of
live fetuses normalized for the number of implantation sites
and also transformed to further normalize the data revealed nostatistically signiﬁcant differences for these two indices. Although
there was no decrease in the proportion of live fetuses per
implantation sites there was a statistically signiﬁcant increase
in resorptions. Therefore, the reduced number of live fetuses
appeared to be a function of both a reduction in the number of
corpora lutea, due to the biological variation inherent in rodent
ovulation, and an increase in resorptions. Resorptions in the high
exposure group were inﬂuenced by total litter loss in one dam
with unexplained weight loss. Exposure to BGVC at similar con-
centrations in rat developmental and two-generation toxicity
studies did not affect the number of live fetuses per litter, estrous
cyclicity, or ovarian pathology (Roberts et al., 2014; Gray et al.,
2014). A range-ﬁnding study conducted with unleaded gasoline
vapor exposures up to 9000 ppm (23,900 mg/m3) reported no
maternal or developmental effects in mice (n = 10/group), in the
pilot test conducted with both mice and rats prior to this
reported study (Roberts et al., 2001).
The BGVC 20,000 mg/m3 target group displayed a transformed
ratio of resorptions to implantations that was statistically signiﬁ-
cantly increased when compared with the control group. One ani-
mal had a strong effect on these data. The litter of this animal was
completely resorbed and therefore only implantation sites were
present in the uterus. This dam also lost 19% of her weight at the
GD 8–11 (26% of her weight from GD 5) interval for no explainable
reason. Since no other losses in maternal body weight were
observed for any other dam in this group, it is unlikely that the
weight loss in this dam was treatment related. However, there
are no data that explains this weight loss, so this dam and her litter
were not excluded from the statistical analysis of the data. Never-
theless, it is useful to note that when this litter was removed from
the statistical analysis of all uterine implantation data to deter-
mine its effect on the implantation data (analysis not reported),
the transformed ratio of resorptions to implantations in the
20,000 mg/m3 target group was no longer statistically signiﬁcant.
In mice, weight loss during gestation has been associated with
increased resorption rates (Chapin et. al., 1993).
In the ﬁrst G/MTBE study there was no evidence of maternal
toxicity, nor any statistically signiﬁcant differences between the
control and treated groups for any of the fetal parameters or obser-
vations. However, a malformation that is rarely observed in control
fetuses, ectopia cordis, was observed in one dead fetus in the
2000 mg/m3 group and in two viable fetuses from a single litter
in the 10,000 mg/m3 group. This malformation was not considered
treatment related for the following reasons: there was no dose–
response demonstrated (the malformation did not occur at the
high dose, 20,000 mg/m3). In addition, fatal malformations are
often associated with increased incidences of early and late resorp-
tions which may cause an observation to be overlooked, but the
20,000 mg/m3 group had a lower incidence of early and late
resorptions than the control group, and thus malformations were
not likely missed due to prenatal deaths at this concentration.
Finally, the two components of G/MTBE (gasoline vapor conden-
sate and methyl t-butyl ether) have both been tested separately
in mice and this malformation was not observed in either study
(Benson et al., 2011; Bevan et al., 1997). In the previous MTBE
study (Bevan et al., 1997), the highest dose evaluated was over-six-
fold higher than the concentration of MTBE in this study. It is inter-
esting to note that ectopia cordis was reported in mice of the same
strain and supplier in a study conducted at a similar time with a
chemically dissimilar ionic liquid, 1-butyl-3-methylimidazolium
chloride (CAS 79917-90-1) (Rasco et al., 2008; Bailey et al.,
2010), but did not occur in the researchers’ earlier study at the
same highest dosage level (Townsend et al., 2006). Genetic drift
may occur in rodent species, particularly mice, but it is difﬁcult
to ascertain possible inﬂuence on developmental toxicity
outcomes.
Table 9
Incidence of selected external malformations in the three studies.
Incidence (No. of fetuses/fetuses examined)
Exposure group (mg/m3) 0 2,000 10,000 20,000 30,000
Ectopia cordis
BGVC – fetuses 0/155 0/167 0/159 0/122 N/A
Litters 0/23 0/25 0/24 0/21 N/A
G/MTBE – fetuses 0/297 0/252 2/303 0/255 N/A
Litters 0/24 0/20 1/25 0/20 N/A
G/MTBE-2 fetuses 0/276 0/336 0/225 0/252 0/407
Litters 0/23 0/21 0/19 0/20 0/33
Gastroschisis
BGVC – fetuses 0/155 0/167 0/159 0/122 N/A
Litters 0/23 0/25 0/24 0/21 N/A
G/MTBE – fetuses 0/297 0/252 1/303 0/255 N/A
Litters 0/24 0/20 1/25 0/20 N/A
G/MTBE-2 fetuses 0/276 0/336 0/225 0/252 1/407
Litters 0/23 0/21 0/19 0/20 1/33
Cleft palate
BGVC – fetuses 0/155 0/167 0/159 0/122 N/A
Litters 0/23 0/25 0/24 0/21 N/A
G/MTBE – fetuses 0/297 0/252 0/303 1/255 N/A
Litters 0/24 0/20 0/25 1/20 N/A
G/MTBE-2 Fetuses 2/276 1/336 1/225 1/252 7/407
Litters 2/23 1/21 1/19 1/20 4/33
Malrotated hindpaw
BGVC – fetuses 3/313 4/338 1/320 2/242 N/A
Litters 3/23 4/25 1/24 2/21 N/A
G/MTBE – fetuses 5/297 2/252 6/303 5/255 N/A
Litters 4/24 2/20 6/25 5/20 N/A
G/MTBE-2 fetuses 0/276 0/336 0/225 0/252 0/407
Litters 0/23 0/21 0/19 0/20 0/33
N/A – not applicable – 30,000 mg/m3 concentration not included in study.
S66 L.G. Roberts et al. / Regulatory Toxicology and Pharmacology 70 (2014) S58–S68The repeat of the G/MTBE study (G/MTBE-2) was conducted to
conﬁrm or refute the ﬁnding of ectopia cordis observed in the ﬁrst
study. In that study the exposure concentrations used were
extended to include a group at 30,000 mg/m3, approximately 75%
of the lower explosive limit. The 30,000 mg/m3 dose group was
exposed on GD 5–10 to encompass the time of embryonic ventral
wall closure, the failure of which is likely responsible for both ecto-
pia cordis and gastroschisis. The group size was increased to 38
plug-positive females to improve the possibility of detection of
the malformation at 30,000 mg/m3. The CD-1 mice used in the ﬁrst
study were from the Charles River facility in Portage, MI; those
used in the repeat study were from the Charles River, Raleigh, NC
facility to preclude the possibility that the fetal ﬁndings in the ﬁrst
study were due to a different spontaneous rate of these two fetal
malformations in the mice at the Portage colony (due to founder
effects, genetic drift, etc.).
The repeat study did not conﬁrm the presence of ectopia cordis
in any mouse fetus at any exposure concentration out of a total of
122 litters and 1396 fetuses. In the absence of a clear dose–
response pattern to the ﬁnding in the ﬁrst study, and the total
absence of the ﬁnding in the repeat study, it is appropriate to con-
clude that the ﬁnding is unlikely to be related to maternal expo-
sure to the test material. In support of this conclusion, ectopia
cordis was not seen in a companion developmental toxicity study
of BGVC in rats conducted at similar concentrations (Roberts
et al., 2014) nor in a two-generation reproductive toxicity study
in rats (Gray et al., 2014).
In the original G/MTBE study a single fetus was observed with
gastroschisis in the 10,000 mg/m3 dose group. In the repeat study,
gastroschisis was also observed in a single fetus in the 30,000
mg/mg3 dose group, and only in the presence of profound develop-
mental toxicity for that fetus (very low body weight and cleft pal-
ate). Historical control data from governmental studies with the
Charles River CD-1 (Swiss) mouse at RTI, with 288 litters and3641 fetuses, show no fetuses with gastroschisis or ectopia cordis.
The historical control data reports 18 fetuses in 11 control litters
(in 6 studies) with cleft palate (1 to 4 litters affected/affected
study) and two fetuses in two control litters (1/litter) with exen-
cephaly in two studies, 1 litter affected/affected study. The absence
of gastroschisis in any of the 3,641 control CD-1 mouse fetuses in
288 control litters lends support to the possibility that gastroschi-
sis in this study may be treatment related, occurring in a compro-
mised fetus at 30,000 mg/m3 with likely concomitant maternal
toxicity. No other historical control data on maternal and fetal ﬁnd-
ings in the Charles River CD-1 mouse could be found in the open
literature. However, gastroschisis was also reported by the authors
who conducted studies with ionic liquids and observed ectopia
cordis in this mouse strain (Bailey et al., 2010) with 1-decyl-3-
methylimidazaolium chloride.
Neither gastroschisis nor ectopia cordis was observed in CD-1
mouse fetuses from mothers exposed to 0, 3600, 14,390, or
28,780 mg/m3 MTBE by whole-body inhalation (in the presence
of maternal and embryofetal toxicity at 14,390 and 28,780mg/m3
MTBE; (Bevan et al., 1997), nor was either of these malformations
observed in the BGVC study. It does not appear that exposure to
either MTBE or gasoline vapor, at atmospheric concentrations
<28,780 mg/m3, causes ectopia cordis or gastroschisis in mice,
and thus it is questionable and certainly not deﬁnitive whether
G/MTBE induced these malformations in these studies. Maternal
ataxia, hypoactivity, prostration, labored breathing, and lacrima-
tion were observed at 14,390 and 28,780 mg/m3 MTBE, and the
resultant stress was considered most likely responsible for (or at
least exacerbated) the increased incidence of fetal cleft palate at
28,780 mg/m3.
No tenable explanation or speciﬁc causes have been identiﬁed
for gastroschisis, a ventral wall defect. One hypothesis is that gas-
troschisis results from an intrauterine interruption of the omphalo-
mesenteric artery (Hoyme et al., 1981). Feldkamp et al. (2007)
Table 10
No observed adverse effect levels.
No observed adverse effect levels (mg/m3)
BGVC G/MTBE G/MTBE-2
Maternal 10,000 20,000 10,000
Reduced body weight and
body weight gain
No adverse
effects
Labored
breathing
Developmental 2000 20,000 20,000
Reduced fetal weight No adverse
effects
Cleft palate
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tral body wall defect through which the gut herniates, leading to
the clinical presentation of gastroschisis. She further speculated
that such a mechanism could explain the origin of other develop-
mental defects of the ventral wall. Another nonvascular explana-
tion for the origin of gastroschisis includes failure of
incorporation of the vitelline duct into the umbilical cord
(Stevenson et al., 2009).
While there are numerous reports associating various drugs and
over-the-counter medications with an increased risk of gastroschi-
sis, none are deﬁnitive. Increased rates of gastroschisis among
infants born to mothers who had used vasoactive medications
(including salicylates, pseudoephedrine and phenylpropanol-
amine) have also been reported (Husain et al., 2008; Werler
et al., 2009), but other evidence is contradictory (Mac Bird et al.,
2009). One of the challenges for interpretation of ectopia cordis
and gastroschisis is that causes for these defects in humans are
not well understood.
The treatment-related increases in absolute (at 10,000 mg/m3)
and relative (at 2000, 10,000, and 20,000 mg/m3) maternal liver
weights in the G/MTBE-2 study are most likely due to the induction
of hepatic metabolizing enzymes, with the concomitant increase in
liver weight (Conney, 1967). This is not considered maternal toxic-
ity, per se, but an adaptive metabolic response to exposure to a
xenobiotic. The absence of an increased liver weight at
30,000 mg/m3 might reﬂect the 7-day interval between the end
of treatment and necropsy of animals in this group.
The incidence of fetal cleft palate in the G/MTBE study was
observed in only one fetus at 20,000 mg/m3 (that study’s highest
concentration). In the repeat study, cleft palate was observed in
all ﬁve groups, including the air control group. An increased inci-
dence of cleft palate observed at 30,000 mg/m3, although not sta-
tistically signiﬁcantly different from the control value, is
considered to be biologically relevant. Cleft palate in fetal mice is
inducible by increased corticosterone levels in the dam (and pre-
sumably transported to the fetuses) (Carmichael et al., 2007;
Senda et al., 2005; Pradat et al., 2003; Hemm et al., 1977).
The presence of fetal cleft palate in all groups, (including the
control group), was not unexpected. Maternal increased corticoste-
rone levels have been attributed to the increased maternal stress
from inhalation study activities such as being moved into and
out of the inhalation chambers, exposure to dynamic air ﬂows,
the absence of feed and water during exposure periods, and no
solid ﬂooring in exposure cages, as well as from test materials at
anesthetic concentrations. In fact, maternal inhalation of MTBE
has been shown to produce cleft palates in fetuses from CD-1
mouse dams which exhibited lethargy and apparent unconscious-
ness (Bevan et al., 1997). Maternal lethargy during exposures was
also observed by laboratory staff during the daily exposure periods
of G/MTBE at 30,000 mg/m3 in the range-ﬁnding study at HLS but
was not reported in the deﬁnitive study. Therefore, the presence of
fetal cleft palate in all groups (including the control group) was not
unexpected, and the increased incidence at 30,000 mg/m3 (from
both inhalation procedures, per se, and the anesthetic qualities of
the MTBE in the G/MTBE at this atmospheric concentration) was
also anticipated.
The increased cleft palate incidence at 30,000 mg/m3 is inter-
preted as exposure-related and most likely secondary to maternal
stress effects. Maternal stress may have also played a role in the
single case of gastroschisis in a compromised (low weight, cleft
palate) fetus developing in a dam exposed to very high levels of
G/MTBE. Since the maternal exposures to 30,000 mg/m3 ended
on GD 10, seven days before necropsy, it is likely that indications
of maternal stress such as increased adrenal weights would have
resolved during the post exposure period (GD 10–17) and were
therefore not present at scheduled necropsy on GD 17.5. Conclusions
Administration of ‘‘baseline’’ gasoline vapor condensates to
mice by whole-body inhalation exposure during the period of
organogenesis and fetal growth produced maternal toxicity that
was evident at the target exposure level of 20,000 mg/m3 as
reduced body weights and body weight change. The target expo-
sure levels of 10,000 mg/m3 and 20,000 mg/m3 produced reduced
fetal body weights. Therefore, the no observable adverse effect lev-
els (NOAELs) for developmental and maternal toxicity in the BGVC
study were considered to be the 2000 and 10,000 mg/m3 target
concentrations, respectively (Table 10). In the G/MTBE study
administration of the test material produced no evidence of mater-
nal toxicity or adverse fetal effects, so the NOAELs are considered
to be 20,000 mg/m3, the highest exposure level, for both develop-
mental and maternal toxicity (Table 10).
In the G/MTBE-2 study, maternal effects were observed at 20,000
and 30,000 mg/m3 and developmental effects at 30,000mg/m3,
resulting in NOAEL values for maternal and developmental toxicity
of 10,000 mg/m3 and 20,000 mg/m3, respectively.
In the G/MTBE-2 study, one fetus with gastroschisis occurred in
the group exposed to the test chemical at 30,000 mg/m3, an expo-
sure level that also produced maternal toxicity during the embry-
onic period of ventral body wall closure. Although there were no
statistically signiﬁcant changes to any of the developmental data
for this study, the developmental NOAEL was selected as the high-
est exposure group without equivocal ﬁndings.
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